RecruitingNCT05898477
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
Sponsor
University of Alabama at Birmingham
Enrollment
2,000 participants
Start Date
May 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
Eligibility
Inclusion Criteria2
- Patients with lymphoma that are fulfilling at least one of the following:
- A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25\>3,900 U/mL and ferritin\>1,000 ng/mL)
Exclusion Criteria2
- Patients developing HLH\> 1 month after lymphoma diagnosis (for aggressive lymphomas)
- Patients with incomplete treatment and response documentation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05898477
Related Trials
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT0685942413 locations
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT0233266817 locations
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
NCT065103091 location
Odronextamab in Low Tumor Volume Advanced FL
NCT071286411 location
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
NCT052943671 location